Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xilio TherapeuticsXLO +1.05%32 EV-to-EBITDA is 2.13 as of Jul. 26, 2026, which is 223% above its 10-year median of 0.66. GuruFocus rates XLO with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 404 Biotechnology companies, Xilio Therapeutics ranks better than 72.28% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Xilio Therapeutics's enterprise value is $-86.89 Mil.
Xilio Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-40.86 Mil. Therefore, Xilio Therapeutics's EV-to-EBITDA for today is 2.13.
The historical rank and industry rank for Xilio Therapeutics's EV-to-EBITDA or its related term are showing as below:
XLO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.51 Med: 0.66 Max: 2.43
Current: 2.13
During the past 7 years, the highest EV-to-EBITDA of Xilio Therapeutics was 2.43. The lowest was -0.51. And the median was 0.66.
XLO's EV-to-EBITDA is ranked better than 72.28% of 404
companies
in the Biotechnology industry
Industry Median: 11.82
vs XLO: 2.13
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Xilio Therapeutics's PE Ratio (TTM) for today is calculated as:
Xilio Therapeutics's share price for today is $8.64.
Xilio Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.550.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Xilio Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Xilio Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xilio Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xilio Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Xilio Therapeutics's EV-to-EBITDA falls into.
Xilio Therapeutics's current Enterprise Value is $-86.89 Mil.
Xilio Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xilio Therapeutics (XLO) has a EV-to-EBITDA of 2.13 as of Jul. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Xilio Therapeutics. This is 223% above median its historical median of 0.66. According to the industry distribution chart, Xilio Therapeutics ranks #112 out of 404 companies in the Biotechnology industry, placing it in the top 27.7%.
Is Xilio Therapeutics' EV-to-EBITDA too high?
Xilio Therapeutics' current EV-to-EBITDA of 2.13 is 223% above median its 10-year median of 0.66. The Biotechnology industry median EV-to-EBITDA is 11.82. Xilio Therapeutics' value of 2.13 is 82% below this industry median. Based on the distribution chart, Xilio Therapeutics ranks #112 out of 404 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Xilio Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Xilio Therapeutics' EV-to-EBITDA compare to FLNA and BSEM?
According to the Biotechnology industry distribution chart, Xilio Therapeutics ranks #112 out of 404 companies for EV-to-EBITDA. This puts Xilio Therapeutics in the upper half of its industry. The industry median EV-to-EBITDA is 11.82. Xilio Therapeutics' value of 2.13 is 82% below this benchmark. While the company's 10-year median is 0.66 vs. the industry median of 11.82, Xilio Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.82, based on 404 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xilio Therapeutics's current EV-to-EBITDA of 2.13 is 82% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Xilio Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 11.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xilio Therapeutics's current EV-to-EBITDA is 2.13, which is 223% above median its own 10-year median of 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xilio Therapeutics stock overvalued right now?
Xilio Therapeutics (XLO) has a current EV-to-EBITDA of 2.13. The current EV-to-EBITDA is 2.13, which is 223% above median its 10-year median of 0.66 and 82% below the Biotechnology industry median of 11.82. Xilio Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Xilio Therapeutics (XLO), the current EV-to-EBITDA is 2.13 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
32GF Score
Get the complete analysis for XLO
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XLO has been successfully added to your 
